2024-08-01 2025-07-31 false Capium Accounts Production 1.1 11451907 2024-08-01 2025-07-31 11451907 bus:FullAccounts 2024-08-01 2025-07-31 11451907 bus:FRS102 2024-08-01 2025-07-31 11451907 bus:AuditExemptWithAccountantsReport 2024-08-01 2025-07-31 11451907 bus:SmallCompaniesRegimeForAccounts 2024-08-01 2025-07-31 11451907 bus:PrivateLimitedCompanyLtd 2024-08-01 2025-07-31 11451907 2024-08-01 2025-07-31 11451907 2025-07-31 11451907 bus:RegisteredOffice 2024-08-01 2025-07-31 11451907 core:WithinOneYear 2025-07-31 11451907 core:AfterOneYear 2025-07-31 11451907 1 2024-08-01 2025-07-31 11451907 bus:Director1 2024-08-01 2025-07-31 11451907 bus:Director1 2025-07-31 11451907 bus:Director1 2023-08-01 2024-07-31 11451907 2023-08-01 11451907 bus:LeadAgentIfApplicable 2024-08-01 2025-07-31 11451907 2023-08-01 2024-07-31 11451907 2024-07-31 11451907 core:WithinOneYear 2024-07-31 11451907 core:AfterOneYear 2024-07-31 11451907 bus:EntityAccountantsOrAuditors 2023-08-01 2024-07-31 11451907 bus:OrdinaryShareClass1 2024-08-01 2025-07-31 11451907 bus:OrdinaryShareClass1 2025-07-31 11451907 bus:OrdinaryShareClass1 2023-08-01 2024-07-31 11451907 bus:OrdinaryShareClass1 2024-07-31 11451907 core:ComputerEquipment 2024-08-01 2025-07-31 11451907 core:ComputerEquipment 2025-07-31 11451907 core:ComputerEquipment 2024-07-31 11451907 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2025-07-31 11451907 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2024-07-31 11451907 core:CostValuation core:Non-currentFinancialInstruments 2025-07-31 11451907 core:CostValuation core:Non-currentFinancialInstruments 2024-07-31 11451907 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2025-07-31 11451907 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2025-07-31 11451907 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-07-31 11451907 core:Non-currentFinancialInstruments 2025-07-31 11451907 core:Non-currentFinancialInstruments 2024-07-31 11451907 core:ShareCapital 2025-07-31 11451907 core:ShareCapital 2024-07-31 11451907 core:RetainedEarningsAccumulatedLosses 2025-07-31 11451907 core:RetainedEarningsAccumulatedLosses 2024-07-31 11451907 core:ShareCapitalOrdinaryShares 2024-08-01 11451907 core:ShareCapitalOrdinaryShares 2023-08-01 11451907 core:ShareCapitalOrdinaryShares 2024-08-01 2025-07-31 11451907 core:ShareCapitalOrdinaryShares 2023-08-01 2024-07-31 11451907 core:ShareCapitalOrdinaryShares 2025-07-31 11451907 core:ShareCapitalOrdinaryShares 2024-07-31 11451907 core:RetainedEarningsAccumulatedLosses 2024-08-01 11451907 core:RetainedEarningsAccumulatedLosses 2023-08-01 11451907 core:RetainedEarningsAccumulatedLosses 2024-08-01 2025-07-31 11451907 core:RetainedEarningsAccumulatedLosses 2023-08-01 2024-07-31 11451907 core:RetainedEarningsAccumulatedLosses 2025-07-31 11451907 core:RetainedEarningsAccumulatedLosses 2024-07-31 11451907 dpl:Item1 2024-08-01 11451907 dpl:Item1 2025-07-31 11451907 dpl:Item1 2023-08-01 11451907 dpl:Item1 2024-07-31 iso4217:GBP xbrli:shares xbrli:pure

Registered Number: 11451907
England and Wales
DR ALSALEH LTD
Unaudited Financial Statements
Period of accounts Start date: 01 August 2024 End date: 31 July 2025

DR ALSALEH LTD Contents Page For the year ended 31 July 2025
Company information | 1
Director's report | 2
Accountants' report | 3
Income statement | 4
Statement of financial position | 5
Notes to the financial statements | 6
Statement of changes in equity | 7

DR ALSALEH LTD Company Information For the year ended 31 July 2025
Director | Darin Hassoun
Registered Number | 11451907
Registered Office | 339 Two Mile Hill Road Kingswood Bristol BS15 1AN
Accountants | Ingle and company limited 339 Two Mile Hill Road Kingswood Bristol BS15 1AN
1

DR ALSALEH LTD Director's Report For the year ended 31 July 2025
Director's report and financial statements The director presents his/her/their annual report and the financial statements for the year ended 31 July 2025. Principal activities Principal activity of the company during the financial year was of specialists medical practice activities. Director The director who served the company throughout the year was as follows:
Darin Hassoun
Statement of director's responsibilities The director is responsible for preparing the directors' report and the financial statements in accordance with applicable law and regulations and in accordance with United Kingdom Generally Accepted Accounting Practice. Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the director must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the profit or loss of the company for that period. In preparing these financial statements, the director is required to : select suitable accounting policies and then apply them consistently make judgements and accounting estimates that are reasonable and prudent state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements and prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business. The director is responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. The director is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. The director is responsible for the maintenance and integrity of the corporate and financial information included on the company's website. Legislation in the United Kingdom, governing the preparation and dissemination of financial statements, may differ from legislation in other jurisdictions On behalf of the board.
---------------------------------- Darin Hassoun Director
Date approved: 07 April 2026 2

DR ALSALEH LTD Accountants' Report For the year ended 31 July 2025
Accountants report You consider that the company is exempt from an audit for the year ended 31 July 2025 . You have acknowledged, on the balance sheet, your responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. These responsibilities include preparing accounts that give a true and fair view of the state of affairs of the company at the end of the financial year and of its profit or loss for the financial year. In accordance with your instructions, we have prepared the accounts which comprise the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the accounting records of the company and on the basis of information and explanations you have given to us. We have not carried out an audit or any other review, and consequently we do not express any opinion on these accounts. Ingle and company limited 31 July 2025 .................................................... Ingle and company limited 339 Two Mile Hill Road Kingswood Bristol BS15 1AN 07 April 2026 3

DR ALSALEH LTD Income Statement For the year ended 31 July 2025
| Notes | 2025 £ |  | 2024 £
--- | --- | --- | --- | ---
Turnover |  | 207,054 |  | 167,824
Cost of sales |  | (3,344) |  | (30,589)
Gross profit |  | 203,710 |  | 137,235
Selling and distribution costs |  | (36,092) |  | (17,467)
Administrative expenses |  | (69,189) |  | (37,001)
Operating profit |  | 98,429 |  | 82,767
Other interest receivable and similar income |  | 143 |  | 315
Profit/(Loss) on ordinary activities before taxation |  | 98,572 |  | 83,082
Tax on profit on ordinary activities |  | (22,433) |  | (18,303)
Profit/(Loss) for the financial year |  | 76,139 |  | 64,779
4

DR ALSALEH LTD Statement of Financial Position As at 31 July 2025
| Notes | 2025 £ |  | 2024 £
--- | --- | --- | --- | ---
Fixed assets |  |  |
Tangible fixed assets | 3 | 543 |  | 775
|  | 543 |  | 775
Current assets |  |  |
Debtors | 4 | 98,400 |  | 111,403
Cash at bank and in hand |  | 33,862 |  | 28,658
|  | 132,262 |  | 140,061
Creditors: amount falling due within one year | 5 | (23,093) |  | (18,963)
Net current assets |  | 109,169 |  | 121,098
Total assets less current liabilities |  | 109,712 |  | 121,873
Net assets |  | 109,712 |  | 121,873
Capital and reserves |  |  |
Called up share capital | 6 | 100 |  | 100
Profit and loss account |  | 109,612 |  | 121,773
Shareholders' funds |  | 109,712 |  | 121,873
For the year ended 31 July 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. Director's responsibilities: The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies. The financial statements were approved by the director on 07 April 2026 and were signed by:
------------------------------- Darin Hassoun Director
5

DR ALSALEH LTD Statement of Changes in Equity For the year ended 31 July 2025
|  | Equity share capital |  | Retained Earnings |  | Total
| £ |  | £ |  | £ |
At 01 August 2023 |  | 100 |  | 109,494 |  | 109,594
Profit for the year |  |  |  | 64,779 |  | 64,779
Total comprehensive income for the year |  | - |  | 64,779 |  | 64,779
Dividends |  |  |  | (52,500) |  | (52,500)
Total investments by and distributions to owners |  | - |  | (52,500) |  | (52,500)
At 31 July 2024 |  | 100 |  | 121,773 |  | 121,873
At 01 August 2024 |  | 100 |  | 121,773 |  | 121,873
Profit for the year |  |  |  | 76,139 |  | 76,139
Total comprehensive income for the year |  | - |  | 76,139 |  | 76,139
Dividends |  |  |  | (88,300) |  | (88,300)
Total investments by and distributions to owners |  | - |  | (88,300) |  | (88,300)
At 31 July 2025 |  | 100 |  | 109,612 |  | 109,712
6

DR ALSALEH LTD Notes to the Financial Statements For the year ended 31 July 2025
General Information DR ALSALEH LTD is a private company, limited by shares, registered in England and Wales, registration number 11451907, registration address 339 Two Mile Hill Road, Kingswood, Bristol, BS15 1AN. The trading address of the company is 30 Great Clover Leaze, Bristol, Avon, BS16 1GG. The presentation currency is £ sterling.
1. | Accounting policies Significant accounting policies Statement of compliance These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006. Basis of preparation The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies. The financial statements are prepared in sterling which is the functional currency of the company. Turnover Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts. Tangible fixed assets Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:
Computer Equipment | 15% Reducing Balance
2. | 0 Average number of employees during the year was 0 (2024 : 0).
3. | Tangible fixed assets
Cost or valuation | Computer Equipment |  | Total
| £ |  | £
At 01 August 2024 | 1,908 |  | 1,908
Additions | - |  | -
Disposals | - |  | -
At 31 July 2025 | 1,908 |  | 1,908
Depreciation
At 01 August 2024 | 1,133 |  | 1,133
Charge for year | 232 |  | 232
On disposals | - |  | -
At 31 July 2025 | 1,365 |  | 1,365
Net book values
Closing balance as at 31 July 2025 | 543 |  | 543
Opening balance as at 01 August 2024 | 775 |  | 775
4. | Debtors: amounts falling due within one year
| 2025 £ |  | 2024 £
--- | --- | --- | ---
Trade Debtors | 0 |  | 13,003
Other Debtors | 98,400 |  | 98,400
| 98,400 |  | 111,403
5. | Creditors: amount falling due within one year
| 2025 £ |  | 2024 £
--- | --- | --- | ---
Corporation Tax | 22,433 |  | 18,303
Accrued Expenses | 660 |  | 660
| 23,093 |  | 18,963
6. | Share Capital
Allotted, called up and fully paid | 2025 £ |  | 2024 £
--- | --- | --- | ---
0 Class A share of £0.00 each | 0 |  | 0
| 0 |  | 0
7